Elucidating Mechanisms Underlying Fibrocyte-Mediated Myelofibrosis Induction in Myelodysplastic Syndromes
Frontiers in Bioscience-Landmark · 2026
DOI: 10.31083/fbl54751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Takaaki Maekawa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Defense Medical College, 359-8513 Tokorozawa, Saitama, Japan. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Myelodysplastic Syndromes, Fibroblasts. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research.
Abstract (Originalsprache)
Background
The mechanism underlying myelofibrosis, which is associated with poor prognosis in myelodysplastic syndromes (MDS), remains unclear.
Methods
We investigated the mechanisms underlying myelofibrosis using peripheral blood mononuclear cells (PBMCs) from healthy donors, MDS92 cell culture supernatants and PolgA/+ and PolgA/A mice treated with high-dose romiplostim as an MDS model. We used the LEGENDplex™ immunoassay to analyze cytokine levels in MDS92 culture supernatants and serum samples from 12 patients with MDS or acute myeloid leukemia with myelodysplasia-related cytogenetic abnormalities.
Results
The MDS92 cell culture supernatants inhibited monocyte differentiation into fibrocytes and contained significantly lower levels of CXCL1 (C-X-C motif chemokine ligand 1), IL-6 (Interleukin-6), and CCL22 (C-C motif chemokine ligand 22) than PBMC culture supernatants from healthy donors. Among serum samples from patients with MDS, IL-18 level was positively correlated with myelofibrosis grade and splenomegaly. In PolgA/A mice, the F4/80high CD11blow/int cell fraction of the spleen was significantly increased following romiplostim administration, compared with PolgA/+ mice; however, worsening of splenomegaly was not observed. Furthermore, reticulin fibers were observed mainly in the subcortical region in all PolgA/+ mice but were rare in the PolgA/A mice.
Conclusions
These findings suggest an association between altered cytokine signaling fibrocyte differentiation, and myelofibrosis in MDS. Further studies are required to clarify how cytokine levels and cellular responsiveness contribute to fibrocyte-mediated myelofibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, National Defense Medical College, 359-8513 Tokorozawa, Saitama, Japan.
- Division of Palliative Care, National Defense Medical College Hospital, 359-8513 Tokorozawa, Saitama, Japan.
- Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, 173-8610, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research
Zitieren
APA
Maekawa, T., Mukai, N., Yanaki, Y., Kemmoku, E., Shonai, T., Kawasaki, K., Sone, T., Takada, K., Ogata, H., Saito, K., Tachi, N., Kawamura, T., Kato, S., Osawa, Y., & Kobayashi, S. (2026). Elucidating Mechanisms Underlying Fibrocyte-Mediated Myelofibrosis Induction in Myelodysplastic Syndromes. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl54751
Vancouver
Maekawa T, Mukai N, Yanaki Y, Kemmoku E, Shonai T, Kawasaki K, et al. Elucidating Mechanisms Underlying Fibrocyte-Mediated Myelofibrosis Induction in Myelodysplastic Syndromes. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl54751
BibTeX
@article{Maekawa2026,
author = {Maekawa, Takaaki and Mukai, Nobuyuki and Yanaki, Yurika and Kemmoku, Emi and Shonai, Takuto and Kawasaki, Kota and Sone, Takehiro and Takada, Kohei and Ogata, Hiraku and Saito, Keita and Tachi, Noriaki and Kawamura, Toshikuni and Kato, Shoichiro and Osawa, Yukiko and Kobayashi, Shinichi},
title = {Elucidating Mechanisms Underlying Fibrocyte-Mediated Myelofibrosis Induction in Myelodysplastic Syndromes},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
doi = {10.31083/fbl54751}
}
EUVIMED